The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study
Current recommendations on the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) essentially derive from small, single-center, retrospective datasets. To obtain larger and better quality data, we carried out the prospective, multice...
Gespeichert in:
Veröffentlicht in: | Catheterization and cardiovascular interventions 2013-12, Vol.82 (7), p.E864-E870 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | E870 |
---|---|
container_issue | 7 |
container_start_page | E864 |
container_title | Catheterization and cardiovascular interventions |
container_volume | 82 |
creator | Schlitt, Axel Rubboli, Andrea Lip, Gregory Y H Lahtela, Heli Valencia, Josè Karjalainen, Pasi P Weber, Michael Laine, Mika Kirchhof, Paulus Niemelä, Matti Vikman, Saila Buerke, Michael Airaksinen, K E Juhani |
description | Current recommendations on the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) essentially derive from small, single-center, retrospective datasets. To obtain larger and better quality data, we carried out the prospective, multicenter Atrial Fibrillation undergoing Coronary Artery Stenting (AFCAS) study. Therefore, consecutive patients with history of or ongoing AF undergoing PCI-S were enrolled, and occurrence of adverse ischemic and bleeding events recorded during 12 months follow-up. In this article, we report the in-hospital observations. Out of the 963 patients, in the majority of cases (49.1%) AF was permanent. The associated risk of stroke, as defined by a CHADS2 -score ≥2, was in 70% of patients moderate to high. Upon enrollment in the registry, 69.3% of patients were on VKA therapy. Overall occurrence of in-hospital major adverse cardiac events was 4.5% (cardiovascular death 1.9%, urgent revascularization in 1.5%, and stroke/arterial thromboembolism in 0.6%). Bleeding complications occurred in 7.1% of patients, being severe in 2.5%. In a logistic regression analysis, no risk factor was independently associated with bleeding events, whereas Clopidogrel treatment decreased and female gender/treatment with gpIIb/IIIa-antagonists, respectively increased the risk for the combined ischemic endpoint. The majority of AF patients undergoing PCI-S are at high stroke risk, and therefore VKA treatment should not be withdrawn and combined anticoagulant and antiplatelet treatment is warranted. Current management appears largely in accordance with current recommendations, whereby accounting for the limited occurrence of in-hospital adverse ischemic and bleeding events. |
doi_str_mv | 10.1002/ccd.25064 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1461340852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1461340852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c245t-e3cf49b476cd98ab74a5da33f75bb5aa0082670d88965c88ffba567536ead0a93</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EohdY8ALIS1ikOL4lYTca0YJUiQVFYhed-DJjlNjBdormNXkinJkpO1Y-kj99_7F_hN7U5KYmhH5QSt9QQSR_hi5rQWnVUPnj-XmuOy4v0FVKPwkhnaTdS3RBWSMFZ80l-vOwN3gCDzszGZ9xsHiG7MqY8G-X9xhydDBi64boxrFcBY8Xr03cBed3eDZRLRm8CUvCKsTgIR6w89nExyJZ6aMm5dXupnkEn4-Wj4Wq9iHNLsNYaciAbQwTzmWhzSn09j-h26ecTSw5B_xtla8XKS_68Aq9sDAm8_p8XqPvt58etp-r-693X7ab-0pRLnJlmLK8G3gjle5aGBoOQgNjthHDIAAIaalsiG7bTgrVttYOIGQjmDSgCXTsGr07eecYfi0m5X5ySZmy7_E3-prLmnHSClrQ9ydUxZBSNLafo5vKC_qa9GuFfamwP1ZY2Ldn7TJMRv8jnzpjfwFoVp7e</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1461340852</pqid></control><display><type>article</type><title>The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Schlitt, Axel ; Rubboli, Andrea ; Lip, Gregory Y H ; Lahtela, Heli ; Valencia, Josè ; Karjalainen, Pasi P ; Weber, Michael ; Laine, Mika ; Kirchhof, Paulus ; Niemelä, Matti ; Vikman, Saila ; Buerke, Michael ; Airaksinen, K E Juhani</creator><creatorcontrib>Schlitt, Axel ; Rubboli, Andrea ; Lip, Gregory Y H ; Lahtela, Heli ; Valencia, Josè ; Karjalainen, Pasi P ; Weber, Michael ; Laine, Mika ; Kirchhof, Paulus ; Niemelä, Matti ; Vikman, Saila ; Buerke, Michael ; Airaksinen, K E Juhani ; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group) ; for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</creatorcontrib><description>Current recommendations on the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) essentially derive from small, single-center, retrospective datasets. To obtain larger and better quality data, we carried out the prospective, multicenter Atrial Fibrillation undergoing Coronary Artery Stenting (AFCAS) study. Therefore, consecutive patients with history of or ongoing AF undergoing PCI-S were enrolled, and occurrence of adverse ischemic and bleeding events recorded during 12 months follow-up. In this article, we report the in-hospital observations. Out of the 963 patients, in the majority of cases (49.1%) AF was permanent. The associated risk of stroke, as defined by a CHADS2 -score ≥2, was in 70% of patients moderate to high. Upon enrollment in the registry, 69.3% of patients were on VKA therapy. Overall occurrence of in-hospital major adverse cardiac events was 4.5% (cardiovascular death 1.9%, urgent revascularization in 1.5%, and stroke/arterial thromboembolism in 0.6%). Bleeding complications occurred in 7.1% of patients, being severe in 2.5%. In a logistic regression analysis, no risk factor was independently associated with bleeding events, whereas Clopidogrel treatment decreased and female gender/treatment with gpIIb/IIIa-antagonists, respectively increased the risk for the combined ischemic endpoint. The majority of AF patients undergoing PCI-S are at high stroke risk, and therefore VKA treatment should not be withdrawn and combined anticoagulant and antiplatelet treatment is warranted. Current management appears largely in accordance with current recommendations, whereby accounting for the limited occurrence of in-hospital adverse ischemic and bleeding events.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.25064</identifier><identifier>PMID: 23765437</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Atrial Fibrillation - complications ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - mortality ; Chi-Square Distribution ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - mortality ; Coronary Artery Disease - therapy ; Europe ; Female ; Guideline Adherence ; Hemorrhage - chemically induced ; Hospital Mortality ; Humans ; Logistic Models ; Male ; Middle Aged ; Percutaneous Coronary Intervention - adverse effects ; Percutaneous Coronary Intervention - instrumentation ; Percutaneous Coronary Intervention - mortality ; Platelet Aggregation Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Prospective Studies ; Registries ; Risk Factors ; Sex Factors ; Stents ; Stroke - etiology ; Stroke - prevention & control ; Thromboembolism - etiology ; Thromboembolism - prevention & control ; Time Factors ; Treatment Outcome</subject><ispartof>Catheterization and cardiovascular interventions, 2013-12, Vol.82 (7), p.E864-E870</ispartof><rights>Copyright © 2013 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c245t-e3cf49b476cd98ab74a5da33f75bb5aa0082670d88965c88ffba567536ead0a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23765437$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schlitt, Axel</creatorcontrib><creatorcontrib>Rubboli, Andrea</creatorcontrib><creatorcontrib>Lip, Gregory Y H</creatorcontrib><creatorcontrib>Lahtela, Heli</creatorcontrib><creatorcontrib>Valencia, Josè</creatorcontrib><creatorcontrib>Karjalainen, Pasi P</creatorcontrib><creatorcontrib>Weber, Michael</creatorcontrib><creatorcontrib>Laine, Mika</creatorcontrib><creatorcontrib>Kirchhof, Paulus</creatorcontrib><creatorcontrib>Niemelä, Matti</creatorcontrib><creatorcontrib>Vikman, Saila</creatorcontrib><creatorcontrib>Buerke, Michael</creatorcontrib><creatorcontrib>Airaksinen, K E Juhani</creatorcontrib><creatorcontrib>AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</creatorcontrib><creatorcontrib>for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</creatorcontrib><title>The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study</title><title>Catheterization and cardiovascular interventions</title><addtitle>Catheter Cardiovasc Interv</addtitle><description>Current recommendations on the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) essentially derive from small, single-center, retrospective datasets. To obtain larger and better quality data, we carried out the prospective, multicenter Atrial Fibrillation undergoing Coronary Artery Stenting (AFCAS) study. Therefore, consecutive patients with history of or ongoing AF undergoing PCI-S were enrolled, and occurrence of adverse ischemic and bleeding events recorded during 12 months follow-up. In this article, we report the in-hospital observations. Out of the 963 patients, in the majority of cases (49.1%) AF was permanent. The associated risk of stroke, as defined by a CHADS2 -score ≥2, was in 70% of patients moderate to high. Upon enrollment in the registry, 69.3% of patients were on VKA therapy. Overall occurrence of in-hospital major adverse cardiac events was 4.5% (cardiovascular death 1.9%, urgent revascularization in 1.5%, and stroke/arterial thromboembolism in 0.6%). Bleeding complications occurred in 7.1% of patients, being severe in 2.5%. In a logistic regression analysis, no risk factor was independently associated with bleeding events, whereas Clopidogrel treatment decreased and female gender/treatment with gpIIb/IIIa-antagonists, respectively increased the risk for the combined ischemic endpoint. The majority of AF patients undergoing PCI-S are at high stroke risk, and therefore VKA treatment should not be withdrawn and combined anticoagulant and antiplatelet treatment is warranted. Current management appears largely in accordance with current recommendations, whereby accounting for the limited occurrence of in-hospital adverse ischemic and bleeding events.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Atrial Fibrillation - complications</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - mortality</subject><subject>Chi-Square Distribution</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - diagnosis</subject><subject>Coronary Artery Disease - mortality</subject><subject>Coronary Artery Disease - therapy</subject><subject>Europe</subject><subject>Female</subject><subject>Guideline Adherence</subject><subject>Hemorrhage - chemically induced</subject><subject>Hospital Mortality</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Percutaneous Coronary Intervention - instrumentation</subject><subject>Percutaneous Coronary Intervention - mortality</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Sex Factors</subject><subject>Stents</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Thromboembolism - etiology</subject><subject>Thromboembolism - prevention & control</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EohdY8ALIS1ikOL4lYTca0YJUiQVFYhed-DJjlNjBdormNXkinJkpO1Y-kj99_7F_hN7U5KYmhH5QSt9QQSR_hi5rQWnVUPnj-XmuOy4v0FVKPwkhnaTdS3RBWSMFZ80l-vOwN3gCDzszGZ9xsHiG7MqY8G-X9xhydDBi64boxrFcBY8Xr03cBed3eDZRLRm8CUvCKsTgIR6w89nExyJZ6aMm5dXupnkEn4-Wj4Wq9iHNLsNYaciAbQwTzmWhzSn09j-h26ecTSw5B_xtla8XKS_68Aq9sDAm8_p8XqPvt58etp-r-693X7ab-0pRLnJlmLK8G3gjle5aGBoOQgNjthHDIAAIaalsiG7bTgrVttYOIGQjmDSgCXTsGr07eecYfi0m5X5ySZmy7_E3-prLmnHSClrQ9ydUxZBSNLafo5vKC_qa9GuFfamwP1ZY2Ldn7TJMRv8jnzpjfwFoVp7e</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Schlitt, Axel</creator><creator>Rubboli, Andrea</creator><creator>Lip, Gregory Y H</creator><creator>Lahtela, Heli</creator><creator>Valencia, Josè</creator><creator>Karjalainen, Pasi P</creator><creator>Weber, Michael</creator><creator>Laine, Mika</creator><creator>Kirchhof, Paulus</creator><creator>Niemelä, Matti</creator><creator>Vikman, Saila</creator><creator>Buerke, Michael</creator><creator>Airaksinen, K E Juhani</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study</title><author>Schlitt, Axel ; Rubboli, Andrea ; Lip, Gregory Y H ; Lahtela, Heli ; Valencia, Josè ; Karjalainen, Pasi P ; Weber, Michael ; Laine, Mika ; Kirchhof, Paulus ; Niemelä, Matti ; Vikman, Saila ; Buerke, Michael ; Airaksinen, K E Juhani</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c245t-e3cf49b476cd98ab74a5da33f75bb5aa0082670d88965c88ffba567536ead0a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Atrial Fibrillation - complications</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - mortality</topic><topic>Chi-Square Distribution</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - diagnosis</topic><topic>Coronary Artery Disease - mortality</topic><topic>Coronary Artery Disease - therapy</topic><topic>Europe</topic><topic>Female</topic><topic>Guideline Adherence</topic><topic>Hemorrhage - chemically induced</topic><topic>Hospital Mortality</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Percutaneous Coronary Intervention - instrumentation</topic><topic>Percutaneous Coronary Intervention - mortality</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Sex Factors</topic><topic>Stents</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Thromboembolism - etiology</topic><topic>Thromboembolism - prevention & control</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schlitt, Axel</creatorcontrib><creatorcontrib>Rubboli, Andrea</creatorcontrib><creatorcontrib>Lip, Gregory Y H</creatorcontrib><creatorcontrib>Lahtela, Heli</creatorcontrib><creatorcontrib>Valencia, Josè</creatorcontrib><creatorcontrib>Karjalainen, Pasi P</creatorcontrib><creatorcontrib>Weber, Michael</creatorcontrib><creatorcontrib>Laine, Mika</creatorcontrib><creatorcontrib>Kirchhof, Paulus</creatorcontrib><creatorcontrib>Niemelä, Matti</creatorcontrib><creatorcontrib>Vikman, Saila</creatorcontrib><creatorcontrib>Buerke, Michael</creatorcontrib><creatorcontrib>Airaksinen, K E Juhani</creatorcontrib><creatorcontrib>AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</creatorcontrib><creatorcontrib>for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schlitt, Axel</au><au>Rubboli, Andrea</au><au>Lip, Gregory Y H</au><au>Lahtela, Heli</au><au>Valencia, Josè</au><au>Karjalainen, Pasi P</au><au>Weber, Michael</au><au>Laine, Mika</au><au>Kirchhof, Paulus</au><au>Niemelä, Matti</au><au>Vikman, Saila</au><au>Buerke, Michael</au><au>Airaksinen, K E Juhani</au><aucorp>AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</aucorp><aucorp>for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Catheter Cardiovasc Interv</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>82</volume><issue>7</issue><spage>E864</spage><epage>E870</epage><pages>E864-E870</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Current recommendations on the management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI-S) essentially derive from small, single-center, retrospective datasets. To obtain larger and better quality data, we carried out the prospective, multicenter Atrial Fibrillation undergoing Coronary Artery Stenting (AFCAS) study. Therefore, consecutive patients with history of or ongoing AF undergoing PCI-S were enrolled, and occurrence of adverse ischemic and bleeding events recorded during 12 months follow-up. In this article, we report the in-hospital observations. Out of the 963 patients, in the majority of cases (49.1%) AF was permanent. The associated risk of stroke, as defined by a CHADS2 -score ≥2, was in 70% of patients moderate to high. Upon enrollment in the registry, 69.3% of patients were on VKA therapy. Overall occurrence of in-hospital major adverse cardiac events was 4.5% (cardiovascular death 1.9%, urgent revascularization in 1.5%, and stroke/arterial thromboembolism in 0.6%). Bleeding complications occurred in 7.1% of patients, being severe in 2.5%. In a logistic regression analysis, no risk factor was independently associated with bleeding events, whereas Clopidogrel treatment decreased and female gender/treatment with gpIIb/IIIa-antagonists, respectively increased the risk for the combined ischemic endpoint. The majority of AF patients undergoing PCI-S are at high stroke risk, and therefore VKA treatment should not be withdrawn and combined anticoagulant and antiplatelet treatment is warranted. Current management appears largely in accordance with current recommendations, whereby accounting for the limited occurrence of in-hospital adverse ischemic and bleeding events.</abstract><cop>United States</cop><pmid>23765437</pmid><doi>10.1002/ccd.25064</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1522-1946 |
ispartof | Catheterization and cardiovascular interventions, 2013-12, Vol.82 (7), p.E864-E870 |
issn | 1522-1946 1522-726X |
language | eng |
recordid | cdi_proquest_miscellaneous_1461340852 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Aged Aged, 80 and over Anticoagulants - adverse effects Anticoagulants - therapeutic use Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Chi-Square Distribution Coronary Artery Disease - complications Coronary Artery Disease - diagnosis Coronary Artery Disease - mortality Coronary Artery Disease - therapy Europe Female Guideline Adherence Hemorrhage - chemically induced Hospital Mortality Humans Logistic Models Male Middle Aged Percutaneous Coronary Intervention - adverse effects Percutaneous Coronary Intervention - instrumentation Percutaneous Coronary Intervention - mortality Platelet Aggregation Inhibitors - therapeutic use Practice Guidelines as Topic Prospective Studies Registries Risk Factors Sex Factors Stents Stroke - etiology Stroke - prevention & control Thromboembolism - etiology Thromboembolism - prevention & control Time Factors Treatment Outcome |
title | The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T18%3A53%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20management%20of%20patients%20with%20atrial%20fibrillation%20undergoing%20percutaneous%20coronary%20intervention%20with%20stent%20implantation:%20in-hospital-data%20from%20the%20Atrial%20Fibrillation%20undergoing%20Coronary%20Artery%20Stenting%20study&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Schlitt,%20Axel&rft.aucorp=AFCAS%20(Management%20of%20patients%20with%20Atrial%20Fibrillation%20undergoing%20Coronary%20Artery%20Stenting%20Study%20Group)&rft.date=2013-12-01&rft.volume=82&rft.issue=7&rft.spage=E864&rft.epage=E870&rft.pages=E864-E870&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.25064&rft_dat=%3Cproquest_cross%3E1461340852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1461340852&rft_id=info:pmid/23765437&rfr_iscdi=true |